Buy Price: $1.65 or better Sell Price: TradersPro Sell Signal Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase […]
Read MorePlus, jobless claims were worse than expected, Regeneron submitted an emergency use authorization request to the FDA for its antibody cocktail, and Morgan Stanley is buying Eaton Vance.
Read MorePlus, President Trump called off stimulus negotiations, Eli Lilly submitted a request to the FDA for emergency use authorization for its experimental COVID-19 antibody treatment, and GE got a Wells notice from the SEC.
Read MorePlus, Trump is back at the White House, House Speaker Pelosi and Treasury Secretary Mnuchin will resume stimulus negotiations today, and Apple announced a new product launch event for October 13 where it is expected to unveil new iPhone models.
Read MorePlus, AMC shares are down as movie theaters close with no big releases until the end of this year, Bristol-Myers Squibb is buying MyoKardia, and Nvidia is building a $52 million supercomputer for Cambridge.
Read MorePlus, initial jobless claims were lower than expected, AstraZeneca shares are down after the FDA said it’s expanding its inquiry into the serious illness of a participant in its COVID vaccine trial, and the CEOs of Facebook, Google, and Twitter will be subpoenaed for testimony by the Senate Commerce Committee.
Read MoreBuy Price: $12.50 or better Sell Price: TradersPro Sell Signal Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric […]
Read MorePlus, several blue-chip companies announced tens of thousands of job cuts, Moderna and Regeneron are up on positive coronavirus drug news, and two software companies went public through direct listings this morning.
Read MorePlus, Goldman Sachs said fears that a delayed U.S. election result could upend the stock market are overblown, Novavax entered a late stage trial for its coronavirus vaccine candidate, and Amazon announced two new Fire TV sticks.
Read MorePlus, President Trump refused to commit to a peaceful transition of power should he lose the November election, last week’s initial jobless claims were higher than expected, and United Airlines is about to start offering rapid coronavirus tests to some fliers to Hawaii.
Read MoreBuy Price: $5.00 or better Sell Price: TradersPro Sell Signal InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product […]
Read MorePlus, Johnson & Johnson started its phase three trial for its possible coronavirus vaccine, Nike shares are up after its earnings report, and Tesla shares are down after its disappointing Battery Day event.
Read MorePlus, Atlanta Fed President Bostic urged Congress to pass additional fiscal support for the U.S. economy, Herman Miller shares surged after the company’s blowout earnings report, and Beyond Meat shares are down following a downgrade.
Read MorePlus, jobless claims were lower than expected for last week though recovery in the labor market appears to be slowing, there’s a glimmer of hope on the stimulus front, and Moderna said it should have data for its late-stage coronavirus vaccine trial in November.
Read MorePlus, Nvidia is buying Arm Holdings in the biggest deal in the semiconductor industry ever, Gilead said it’s continuing to study new ways to use its remdesivir treatment for the coronavirus, and Delta said it is borrowing $6.5 billion backed by its frequent-flyer program.
Read More